Rowell N P, Gilmore O J, Plowman P N
Hum Toxicol. 1987 May;6(3):227-32. doi: 10.1177/096032718700600310.
Seventy-nine postmenopausal patients received aminoglutethimide (AG; 750 mg daily) and hydrocortisone therapy for metastatic or locally recurrent breast cancer following the failure of other hormonal therapy. Fourteen of 64 patients, tolerating the drug and assessable for response, achieved a complete or partial response. Disease stabilisation occurred in a further 2 patients giving a response rate of 25% in these patients. Median duration of response was 10 months. Response rates to AG were not significantly different whether or not there had been a response to previous hormonal therapy but a trend to higher response rates in ER rich tumours was observed. Those with a longer interval from first relapse to the start of AG appeared more likely to respond. Side-effects were noted in 35 patients overall (44%) and in 70% of those over the age of 65 years. Treatment was discontinued because of toxicity in 10 patients and there was one death due to agranulocytosis. AG is active in postmenopausal breast cancer following failure of first-line hormonal therapy, toxicity limiting its use earlier in the disease.
79名绝经后患者在其他激素治疗失败后，接受氨鲁米特（AG；每日750毫克）和氢化可的松治疗转移性或局部复发性乳腺癌。64名耐受该药物且可评估反应的患者中，14名实现了完全或部分缓解。另有2名患者病情稳定，这些患者的缓解率为25%。缓解的中位持续时间为10个月。无论之前的激素治疗是否有反应，AG的反应率均无显著差异，但观察到雌激素受体丰富的肿瘤有更高反应率的趋势。从首次复发到开始使用AG的间隔时间较长的患者似乎更有可能产生反应。总体上35名患者（44%）出现了副作用，65岁以上患者中有70%出现副作用。10名患者因毒性而停药，有1例因粒细胞缺乏症死亡。AG在一线激素治疗失败后的绝经后乳腺癌中具有活性，毒性限制了其在疾病早期的使用。
